Pharma Futures 3: Emerging Opportunities

Emerging markets are now significant players in global trade. Yet they are also very different than mature markets and more complex to manage. For the pharmaceutical industry in particular, they have often presented both commercial opportunities and the challenge of massive poverty and low levels of access to healthcare.

It is not surprising that many global pharma companies have entered these markets slowly and somewhat reluctantly. However, emerging markets are also vitally important for the industry, offering an opportunity to refocus business models in a way that both creates business value and expands access to healthcare.

Pharma Futures 3: Emerging Opportunities (Download Report) is a solutions-focused initiative that explores the link between sustainable pharmaceutical business models and global health outcomes in emerging markets.


It is an extension of the successful Pharma Futures (www.pharmafutures.org) series of investor-led dialogues exploring the future of the pharmaceutical industry. These were based on the premise that a better alignment between corporate profitability and society’s need for improved access to affordable healthcare, including medicines, is a prerequisite for a thriving healthcare industry.

Press Release: Emerging Markets offer promise and challenge to the pharmaceutical industry: Investor Report (February 26, 2009)

Launched February 26, 2009, in London, United Kingdom, Pharma Futures 3 is a record of year-long, structured dialogues between the pharmaceutical industry, institutional investors, global health experts and social entrepreneurs about the challenges and opportunities of delivering healthcare in emerging markets. The aim of the dialogues was to collaboratively identify new growth models in these markets, and novel approaches to funding and partnerships to expand access and develop new products for the poorest populations.

SustainAbility would like to thank and acknowledge the project participants:

• APG Investments
  
• Aravind
  
• AstraZeneca
  
• Avesthagen
  
• Bill and Melinda Gates Foundation
  
• CGD
  
• cga
  
• Dr Reddy’s
  
• Generation Investment
  
• GSK
  
• Johnson & Johnson – Pharmaceuticals Group
  
• Mehta Partners
  
• Novartis
  
• PATH
  
• Project Impact
  
• Robeco
  
• Stewart Adkins Advisors Limited
  
• USS

SustainAbility would also like to thank a number of external experts who contributed to the Pharma Futures 3 process.

Media Coverage for Pharma Futures 3: Emerging Opportunities

• Professional Pensions
  USS and APG publish Pharma Futures report
  26 February 2009
  
  
• PharmaLive
  Emerging Markets offer promise and challenge to the pharmaceutical industry: Investor Report
  26 February 2009
  
  
• I&PE (Investment and Pension Funds Europe)
  Pension funds urge new direction in pharmaceuticals
  26 February 2009
  
  
• Global Pensions
  USS and APG publish Pharma Futures report
  26 February 2009

For more information on the report or SustainAbility’s related activities, contact:

Maggie Brenneke, Director, Client Services
brenneke@sustainability.com